Medical treatment of ulcerative colitis

Gastroenterologia Polska

Volumn 15, Issue 6, 2008, Pages 359-367

  Błoński, Wojciech ^a,b   Lichtenstein, Gary R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Induction of remission; Maintenance of remission; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID DERIVATIVE; CORTISONE; CYCLOSPORIN A; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; OLSALAZINE; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

ACNE; BODY WEIGHT; BONE NECROSIS; CATARACT; CLINICAL TRIAL; COLON RESECTION; DECISION MAKING; DIZZINESS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DYSPEPSIA; DYSPNEA; EVIDENCE BASED PRACTICE; FLUSHING; GINGIVA HYPERPLASIA; GROWTH RETARDATION; HAIR LOSS; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; INFECTION; INJECTION SITE IRRITATION; INSOMNIA; LEG EDEMA; LEUKOPENIA; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MONOTHERAPY; MOOD CHANGE; MYOPATHY; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PRURITUS; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; SEIZURE; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; TREMOR; ULCERATIVE COLITIS;

EID: 70449587024     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Su C., Lichtenstein G.: Ulcerative colitis. [in:] Sleisenger and Fordtran's gastrointestinal and liver disease, (eds) M. Feldman, L. Friedman, L. Brandt. Saunsanders Elsevier, Philadelphia 2006, 2499-2549.
2. Langholz E., Munkholm P., Davidsen M., Binder V.: Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology, 1994, 1, 3-11.
3. Langholz E., Munkholm P., Nielsen O.H., Kreiner S., Binder V.: Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand. J. Gastroenterol., 1991, 12, 1247-1256.
4. Hendriksen C., Kreiner S., Binder V.: Long term prognosis in ulcerative colitis - based on results from a regional patient group from the county of Copenhagen. Gut, 1985, 2, 158-163.
5. Stonnington C.M., Phillips S.F., Zinsmeister A.R., Melton L.J. 3rd.: Prognosis of chronic ulcerative colitis in a community. Gut, 1987, 10, 1261-1266.
6. Sutherland L., Macdonald J.K.: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2006, 2, CD000543.
7. Hanauer S., Schwartz J., Robinson M., Roufail W., Arora S., Cello J., Safdi M.: Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am. J. Gastroenterol., 1993, 8, 1188-1197.
8. Hanauer S., Barish C., Pambianco D., Sigmon R., Gannan R., Koval G.: A multicenter, double-blind, placebo-controlled, doseranging trial of olsalazine formildmoderately active ulcerative colitis. Gastroenterology, 1996, 110, A921.
9. Hetzel D., Bochner F., Imhoff D., Gibson G., Fitch R., Hecker R.: Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology, 1985, 88, A1418.
10. Robinson M., Gitnick G., Balart L., Das K., Turkin D.: Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology, 1988, 84, A381.
11. Schroeder K.W., Tremaine W.J., Ilstrup D.M.: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med., 1987, 26, 1625-1629.
12. Sninsky C.A., Cort D.H., Shanahan F., Powers B.J., Sessions J.T., Pruitt R.E., Jacobs W.H., Lo S.K., Targan S.R., Cerda J.J., et al.: Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann. Intern. Med., 1991, 5, 350-355.
13. Sutherland L., Robinson M., Onstad G., Peppercorn M., Greenberger N., Goodman M.: A double-blind, placebo-controlled, multicentre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Can. J. Gastroenterol., 1990, 4, 463-467.
14. Zinberg J., Molinas S., Das K.M.: Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am. J. Gastroenterol., 1990, 5, 562-566.
15. Fleig W.E., Laudage G., Sommer H., Wellmann W., Stange E.F., Riemann J.: Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion, 1988, 3, 173-180.
16. Good L., Nester T., Borgen L.: A double-blind comparison of controlled release mesalamine tablets and sulfasalazine in the treatment of ulcerative colitis. Gastroenterology, 1992, 102, A630.
17. Jiang X.L., Cui H.F.: Different therapy for different types of ulcerative colitis in China. World J. Gastroenterol., 2004, 10, 1513-1520.
18. Munakata A., Yoshida Y., Muto T., Tsuchiya S., Fukushima T., Hiwatashi N., Kobayashi K., Kitano A., Shimoyama T., Inoue M., et al. : Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. J. Gastroenterol., 1995, 30, 108-111.
19. Rachmilewitz D.: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ, 1989, 6666, 82-86.
20. Rao S.S., Dundas S.A., Holdsworth C.D., Cann P.A., Palmer K.R., Corbett C.L.: Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut, 1989, 5, 675-679.
21. Willoughby C.P., Cowan R.E., Gould S.R., Machell R.J., Stewart J.B.: Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. Scand. J. Gastroenterol. Suppl., 1988, 148, 40-44.
22. Riley S.A., Mani V., Goodman M.J., Herd M.E., Dutt S., Turnberg L.A.: Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut, 1988, 5, 669-674.
23. Riley S.A., Lecarpentier J., Mani V., Goodman M.J., Mandal B.K., Turnberg L.A.: Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. Gut, 1987, 8, 1008-1012.
24. Kjaergaard N., Christensen L.A., Lauritsen J.G., Rasmussen S.N., Hansen S.H.: Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis. Scand. J. Gastroenterol., 1989, 7, 891-896.
25. Sutherland L., Macdonald J.K.: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2006, 2, CD000544.
26. Sandberg-Gertzen H., Jarnerot G., Kraaz W.: Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology, 1986, 4, 1024-1030.
27. Wright J.P., O'Keefe E.A., Cuming L., Jaskiewicz K.: Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig. Dis. Sci., 1993, 10, 1837-1842.
28. Miner P., Hanauer S., Robinson M., Schwartz J., Arora S.: Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig. Dis. Sci., 1995, 2, 296-304.
29. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann. Intern. Med., 1996, 2, 204-211.
30. Hawkey C.J., Dube L.M., Rountree L.V., Linnen P.J., Lancaster J.F.: A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology, 1997, 3, 718-724.
31. Andreoli A., Cosintino R., Trotti R., Berri F., Prantera C.: 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission [abstract]. Clinical Controversies in Inflammatory Bowel Disease, 1987, 170.
32. Ardizzone S., Petrillo M., Molteni P., Desideri S., Bianchi Porro G.: Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. J. Clin. Gastroenterol., 1995, 4, 287-289.33.
33. Ireland A., Mason C.H., Jewell D.P.: Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut, 1988, 6, 835-837.
34. Kiilerich S., Ladefoged K., Rannem T., Ranlov P.J.: Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Gut, 1992, 2, 252-255.
35. Kruis W., Judmaier G., Kayasseh L., Stolte M., Theuer D., Scheurlen C., Hentschel E., Kratochvil P.: Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur. Gastroenterol. Hepatol., 1995, 5, 391-396.
36. McIntyre P.B., Rodrigues C.A., Lennard-Jones J.E., Barrison I.G., Walker J.G., Baron J.H., Thornton P.C.: Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment. Pharmacol. Ther., 1988, 3, 237-243.
37. Mulder C.J., Tytgat G.N., Weterman I.T., Dekker W., Blok P., Schrijver M., van der Heide H.: Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology, 1988, 6, 1449-1453.
38. Nilsson A., Danielsson A., Lofberg R., Benno P., Bergman L., Fausa O., Florholmen J., Karvonen A.L., Kildebo S., Kollberg B., et al. : Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am. J. Gastroenterol., 1995, 3, 381-387.
39. Rijk M.C., van Lier H.J., van Tongeren J.H.: Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group. Am. J. Gastroenterol., 1992, 4, 438-442.
40. Riley S.A., Mani V., Goodman M.J., Herd M.E., Dutt S., Turnberg L.A.: Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology, 1988, 6, 1383-1389.
41. Rutgeerts P.: Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment. Pharmacol. Ther., 1989, 2, 183-191.
42. Lichtenstein G.R., Kamm M.A., Boddu P., Gubergrits N., Lyne A., Butler T., Lees K., Joseph R.E., Sandborn W.J.: Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol., 2007, 1, 95-102.
43. Kamm M.A., Sandborn W.J., Gassull M., Schreiber S., Jackowski L., Butler T., Lyne A., Stephenson D., Palmen M., Joseph R.E.: Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology, 2007, 1, 66-75, 432-433.
44. Lichtenstein G.R., Kamm M.A., Sandborn W.J., Lyne A., Joseph R.E.: MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment. Pharmacol. Ther., 2008, 11, 1094-1102.
45. Kamm M.A., Lichtenstein G.R., Sandborn W.J., Schreiber S., Lees K., Barrett K., Joseph R.: Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut, 2008, 7, 893-902.
46. Stein R.B., Hanauer S.B.: Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf., 2000, 5, 429-448.
47. Lichtenstein G.R., Abreu M.T., Cohen R., Tremaine W.: American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology, 2006, 3, 935-939.
48. Marshall J.K., Irvine E.J.: Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut, 1997, 6, 775-781.
49. Cohen R.D., Woseth D.M., Thisted R.A., Hanauer S.B.: A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am. J. Gastroenterol., 2000, 5, 1263-1276.
50. Mulder C.J., Fockens P., Meijer J.W., van der Heide H., Wiltink E.H., Tytgat G.N.: Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur. J. Gastroenterol. Hepatol., 1996, 6, 549-553.
51. Danielsson A., Hellers G., Lyrenas E., Löfberg R., Nilsson A., Olsson O., Olsson S.A., Persson T., Salde L., Naesdal J., et al. : A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand. J. Gastroenterol., 1987, 8, 987-992.
52. Bianchi Porro G., Prantera C., Campieri M.: Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis. Eur. J. Gastroenterol. Hepatol., 1994, 6, 125-130.
53. Lemann M., Galian A., Rutgeerts P., Van Heuverzwijn R., Cortot A., Viteau J.M., Elewaut A., Belaiche J., Froguel E., Modigliani R.: Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment. Pharmacol. Ther., 1995, 5, 557-562.
54. Truelove S.C., Witts L.J.: Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br. Med. J., 1954, 4884, 375-378.
55. Truelove S.C., Witts L.J.: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J., 1955, 4947, 1041-1048.
56. Truelove S.C., Watkinson G., Draper G.: Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br. Med. J., 1962, 5321, 1708-1711.
57. Faubion W.A. Jr., Loftus E.V. Jr., Harmsen W.S., Zinsmeister A.R., Sandborn W.J.: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology, 2001, 2, 255-260.
58. Lichtenstein G.R., Abreu M.T., Cohen R., Tremaine W.: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology, 2006, 3, 940-987.
59. Truelove S.C., Jewell D.P.: Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet, 1974, 7866, 1067-1070.
60. Truelove S.C., Willoughby C.P., Lee E.G., Kettlewell M.G.: Further experience in the treatment of severe attacks of ulcerative colitis. Lancet, 1978, 8099, 1086-1088.
61. Meyers S., Sachar D.B., Goldberg J.D., Janowitz H.D.: Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology, 1983, 2, 351-357.
62. Jarnerot G., Rolny P., Sandberg-Gertzen H.: Intensive intravenous treatment of ulcerative colitis. Gastroenterology, 1985, 5, 1005-1013.
63. Truelove S.C., Witts L.J.: Cortisone and corticotrophin in ulcerative colitis. Br. Med. J., 1959, 5119, 387-394.
64. Lennard-Jones J.E., Misiewicz J.J., Connell A.M., Baron J.H., Jones F.A.: Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet, 1965, 7378, 188-189. .
65. Powell-Tuck J., Bown R.L., Chambers T.J., Lennard-Jones J.E.: A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion, 1981, 5, 263-270.
66. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., Bianchi Porro G.: Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut, 2006, 1, 47-53.
67. Kirk A.P., Lennard-Jones J.E.: Controlled trial of azathioprine in chronic ulcerative colitis. Br. Med. J. (Clin. Res. Ed.), 1982, 6325, 1291-1292.
68. Rosenberg J.L., Wall A.J., Levin B., Binder H.J., Kirsner J.B.: A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology, 1975, 1, 96-99.
69. Jewell D.P., Truelove S.C.: Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br. Med. J., 1974, 5945, 627-630.
70. Caprilli R., Carratu R., Babbini M.: Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. Am. J. Dig. Dis., 1975, 2, 115-120.
71. Mantzaris G.J., Petraki K., Sfakianakis M., Petraki K., Christidou A., Karagiannidis A., Triadaphyllou G.: A prospective, randomized trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroiddependent ulcerative colitis. Gastroenterology, 2001, 120, A-127.
72. Mantzaris G.J., Sfakianakis M., Archavlis E., Petraki K., Christidou A., Karagiannidis A., Triadaphyllou G.: A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am. J. Gastroenterol., 2004, 6, 1122-1128.
73. Hawthorne A.B., Logan R.F., Hawkey C.J., Foster P.N., Axon A.T., Swarbrick E.T., Scott B.B., Lennard-Jones J.E.: Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ, 1992, 6844, 20-22.
74. Kandiel A., Fraser A.G., Korelitz B.I., Brensinger C., Lewis J.D.: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut, 2005, 8, 1121-1125.
75. Dayharsh G.A., Loftus E.V. Jr., Sandborn W.J., Tremaine W.J., Zinsmeister A.R., Witzig T.E., Macon W.R., Burgart L.J.: Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6- mercaptopurine. Gastroenterology, 2002, 1, 72-77.
76. Aithal G.P., Mansfield J.C.: Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment. Pharmacol. Ther., 2001, 8, 1101-1108.
77. Connell W.R., Kamm M.A., Ritchie J.K., Lennard-Jones J.E.: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut, 1993, 8, 1081-1085.
78. Colombel J.F., Ferrari N., Debuysere H., Marteau P., Gendre J.P., Bonaz B., Soulé J.C., Modigliani R., Touze Y., Catala P., Libersa C., Broly F.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology, 2000, 6, 1025-1030.
79. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Théorȩt Y., Seidman E.G.: Pharmacogenomics and metabolite measurement for 6- mercaptopurine therapy in inflammatory bowel disease. Gastroenterology, 2000, 4, 705-713.
80. Present D.H., Krumholz M.P., Wolke A., Korelitz B.L.: 6-Mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann. Intern. Med., 1989, 8, 641-649.
81. Bouhnik Y., Lemann M., Mary J.Y., Scemama G., Tad' R., Matuchansky C., Modigliani R., Rambaud J.C.: Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet, 1996, 8996, 215-219.
82. Cheng B.L.G.: Are individuals with Crohn's disease who are intolerant to 6-mercaptopurine able to tolerate azathioprine? Gastroenterology, 2000, 118, A1336.
83. Borel J.F., Feurer C., Gubler H.U., Stahelin H.: Biological effects of cyclosporin A: a new antilymphocytic agent. 1976. Agents Actions, 1994, 3-4, 79-86.
84. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., Michelassi F., Hanauer S.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med., 1994, 26, 1841-1845.
85. Bianchi Porro G., Petrillo M., Ardizzone S.: Cyclosporin treatment for severe active ulcerative colitis. Lancet, 1990, 8712, 439.
86. Gupta S., Keshavarzian A., Hodgson H.J.: Cyclosporin in ulcerative colitis. Lancet, 1984, 8414, 1277-1278.
87. Hyams J.S., Treem W.R.: Cyclosporine treatment of fulminant colitis. J. Pediatr. Gastroenterol. Nutr., 1989, 3, 383-387.
88. Lichtiger S., Present D.H.: Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet, 1990, 8706, 16-19.
89. Campbell S., Travis S., Jewell D.: Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur. J. Gastroenterol. Hepatol., 2005, 1, 79-84.
90. Cohen R.D., Stein R., Hanauer S.B.: Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am. J. Gastroenterol., 1999, 6, 1587-1592.
91. Oren R., Arber N., Odes S., Moshkowitz M., Keter D., Pomeranz I., Ron Y., Reisfeld I., Broide E., Lavy A., Fich A., Eliakim R., Patz J., Bardan E., Villa Y., Gilat T.: Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology, 1996, 5, 1416-1421.
92. Remicade (Infliximab). Prescribing information. 2005.
93. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., Travers S., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., de Villiers W.J., Present D., Sands B.E., Colombel J.F.: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 23, 2462-2476.
94. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Hanauer S.B.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology, 2004, 2, 402-413.
95. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., Rutgeerts P.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med., 2003, 7, 601-608.
96. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Rutgeerts P.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002, 9317, 1541-1549.
97. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., Kamm M.A., Korzenik J.R., Lashner B.A., Onken J.E., Rachmilewitz D., Rutgeerts P., Wild G., Wolf D.C., Marsters P.A., Travers S.B., Blank M.A., van Deventer S.J.: Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med., 2004, 9, 876-885.
98. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., Mayer L., Van Hogezand R.A., Braakman T., DeWoody K.L., Schaible T.F., Van Deventer S.J.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology, 1999, 4, 761-769.
99. Rutgeerts P., Van Assche G., Vermeire S.: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology, 2004, 6, 1593-1610
100. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm. Rep., 2000, RR-6, 1-51.